Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corneal Neurotization vs Cenergermin for Neurotrophic Keratitis
NCT07073729Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of cenegermin in neurotrophic keratitis (NK) (2 arms). Primary endpoint: Change in Corneal Sensitivity at 12 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
cenegermin
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on NCT07073729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073729.